4.7 Review

The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV

期刊

ANTIVIRAL RESEARCH
卷 80, 期 3, 页码 231-238

出版社

ELSEVIER
DOI: 10.1016/j.antiviral.2008.07.006

关键词

Hepatitis B; Hepatitis C; Viral hepatitis; Animal model; Chimpanzee; uPA; Chimeric mice; Antiviral therapy; Neutralizing antibodies

资金

  1. Ghent University [01G00507]
  2. Belgian State via the Interuniversity Attraction Poles Program [P6/36-HEPRO]
  3. Research Foundation Flanders (FWO-Vlaanderen)

向作者/读者索取更多资源

The study of the hepatitis B virus (HBV) and the hepatitis C virus (HCV) has long been hampered by the lack of a suitable small animal model. Both viruses could only be studied in humans or in chimpanzees. Recently, a new chimeric mouse model was developed that was permissive for HBV and HCV infection. In this model, uPA(+/+)-SCID mice, suffering from a transgene-induced liver disease, are transplanted early after birth with primary human hepatocytes. These human hepatocytes integrate in the parenchyma and progressively repopulate the diseased mouse liver without losing their normal metabolic functions. Successfully transplanted mice can then be infected with HBV and HCV. In this review, we describe the characteristics of this chimeric mouse model in more detail and give an overview of how this model has already contributed to the development of new antiviral compounds for the treatment of viral hepatitis. (C) 2008 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据